Abstract
Since the RNAi mechanisms were established in 1990, the rapid progression of RNAi application from animal to clinical trails in human diseases has shown its enormous therapeutic potential. In this review, RNAi therapeutics in allergic diseases is discussed, from RNAi mechanisms and design to challenges and potential targets in allergic diseases. Current reported studies on investigating RNAi therapy in vitro and in vivo are also reviewed. Although there are promising studies in RNAi-based therapy, understanding further the detailed mechanisms of RNAi-based therapy and investigating more effective delivery methods are required for future development.
Keywords: Allergy, RNAi, siRNA, shRNA, gene therapy, transcription factor, cytokine, susceptibility genes
Current Gene Therapy
Title: RNA Interference: New Therapeutics in Allergic Diseases
Volume: 8 Issue: 4
Author(s): Chen-Chen Lee and Bor-Luen Chiang
Affiliation:
Keywords: Allergy, RNAi, siRNA, shRNA, gene therapy, transcription factor, cytokine, susceptibility genes
Abstract: Since the RNAi mechanisms were established in 1990, the rapid progression of RNAi application from animal to clinical trails in human diseases has shown its enormous therapeutic potential. In this review, RNAi therapeutics in allergic diseases is discussed, from RNAi mechanisms and design to challenges and potential targets in allergic diseases. Current reported studies on investigating RNAi therapy in vitro and in vivo are also reviewed. Although there are promising studies in RNAi-based therapy, understanding further the detailed mechanisms of RNAi-based therapy and investigating more effective delivery methods are required for future development.
Export Options
About this article
Cite this article as:
Lee Chen-Chen and Chiang Bor-Luen, RNA Interference: New Therapeutics in Allergic Diseases, Current Gene Therapy 2008; 8 (4) . https://dx.doi.org/10.2174/156652308785160692
DOI https://dx.doi.org/10.2174/156652308785160692 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Specific Targeted Therapy: A New Tool for the Destruction of Cancer
Current Drug Therapy Protective Effects of Caffeic Acid and the Alzheimer's Brain: An Update
Mini-Reviews in Medicinal Chemistry Targeting Astrocytes for Treatment in Amyotrophic Lateral Sclerosis
Current Pharmaceutical Design Melatonin and Melatonergic Influence on Neuronal Transcription Factors: Implications for the Development of Novel Therapies for Neurodegenerative Disorders
Current Neuropharmacology The AMP-Activated Protein Kinase: Role in Regulation of Skeletal Muscle Metabolism and Insulin Sensitivity
Mini-Reviews in Medicinal Chemistry DL-3-n-Butylphthalide, an Anti-Oxidant Agent, Prevents Neurological Deficits and Cerebral Injury Following Stroke per Functional Analysis, Magnetic Resonance Imaging and Histological Assessment
Current Neurovascular Research Immunotherapeutic Approaches in MS: Update on Pathophysiology and Emerging Agents or Strategies 2006
Endocrine, Metabolic & Immune Disorders - Drug Targets Incretin Analogues that have been Developed to Treat Type 2 Diabetes Hold Promise as a Novel Treatment Strategy for Alzheimers Disease
Recent Patents on CNS Drug Discovery (Discontinued) Transgenic Mouse Models of Alzheimer Disease: Developing a Better Model as a Tool for Therapeutic Interventions
Current Pharmaceutical Design Neurodegenerative Disorders and the Current State, Pathophysiology, and Management of Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Antiinflammatory Activity of Melatonin in Central Nervous System
Current Neuropharmacology Application of Resveratrol in Diabetes: Rationale, Strategies and Challenges
Current Molecular Medicine Phytochemicals in the Treatment of Alzheimer’s Disease: A Systematic Review
Current Drug Targets Functionalized magnetic nanoparticles for biomedical applications
Current Pharmaceutical Design Transient Receptor Potential Channels - Emerging Novel Drug Targets for the Treatment of Pain
Current Medicinal Chemistry The Use of Stem Cells for the Treatment of Spinal Surgical Conditions.
Current Stem Cell Research & Therapy Metal Protein Attenuating Compounds (MPACs): An Emerging Approach for the Treatment of Neurodegenerative Disorders
Current Bioactive Compounds Inhibitors and Breakers of Advanced Glycation Endproducts (AGEs): A Review
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Molecular Mechanisms and Therapeutic Application of NSAIDs and Derived Compounds in Alzheimers Disease
Current Alzheimer Research AFM-Based Single Molecule Techniques: Unraveling the Amyloid Pathogenic Species
Current Pharmaceutical Design